Javascript must be enabled to continue!
Analysis of Mycobacterium Species for the Presence of a Macrolide Toxin, Mycolactone
View through CrossRef
ABSTRACT
Mycobacterium ulcerans
is an environmental organism which is responsible for the disease Buruli ulcer, a necrotizing skin disease emerging in west Africa.
M. ulcerans
produces the polyketide-derived macrolide mycolactone, which is required for the immunosuppression and tissue damage which characterizes Buruli ulcer. We have extracted lipids from the cell envelope and culture filtrate from 52 isolates of
Mycobacterium
species, analyzed them with thin-layer chromatography, and tested them in a murine fibroblast cell line (L929) cytotoxicity assay to investigate whether these mycobacterial species produce mycolactone. For these studies chloroform-methanol (2:1, vol/vol) extracts were prepared from representative fast- and slow-growing mycobacterial species. Isolates tested included 16 uncharacterized, slow-growing, environmental mycobacterial species isolated from areas in which
M. ulcerans
infection is endemic. Although several strains of mycobacteria studied produced cytopathic lipids, none of these produced a phenotype on cultured cells consistent with that produced by mycolactone. Two mycobacterial species,
M. scrofulaceum
and
M. kansasii
, and eight of the environmental mycobacterial isolates contained cell-associated lipids cytopathic to fibroblasts at concentrations of 33 to 1,000 μg/ml. In contrast, mycolactone produces cytotoxicity at less than 2 ng/ml. Analysis of 16S rRNA sequences from the eight environmental isolates suggests that these are novel mycobacterial species. Results from these studies suggest that, although production of cytopathic lipids is relatively common among mycobacterial species, the production of mycolactone as a cell-associated or secreted molecule appears so far to be restricted to
M. ulcerans
.
American Society for Microbiology
Title: Analysis of
Mycobacterium
Species for the Presence of a Macrolide Toxin, Mycolactone
Description:
ABSTRACT
Mycobacterium ulcerans
is an environmental organism which is responsible for the disease Buruli ulcer, a necrotizing skin disease emerging in west Africa.
M.
ulcerans
produces the polyketide-derived macrolide mycolactone, which is required for the immunosuppression and tissue damage which characterizes Buruli ulcer.
We have extracted lipids from the cell envelope and culture filtrate from 52 isolates of
Mycobacterium
species, analyzed them with thin-layer chromatography, and tested them in a murine fibroblast cell line (L929) cytotoxicity assay to investigate whether these mycobacterial species produce mycolactone.
For these studies chloroform-methanol (2:1, vol/vol) extracts were prepared from representative fast- and slow-growing mycobacterial species.
Isolates tested included 16 uncharacterized, slow-growing, environmental mycobacterial species isolated from areas in which
M.
ulcerans
infection is endemic.
Although several strains of mycobacteria studied produced cytopathic lipids, none of these produced a phenotype on cultured cells consistent with that produced by mycolactone.
Two mycobacterial species,
M.
scrofulaceum
and
M.
kansasii
, and eight of the environmental mycobacterial isolates contained cell-associated lipids cytopathic to fibroblasts at concentrations of 33 to 1,000 μg/ml.
In contrast, mycolactone produces cytotoxicity at less than 2 ng/ml.
Analysis of 16S rRNA sequences from the eight environmental isolates suggests that these are novel mycobacterial species.
Results from these studies suggest that, although production of cytopathic lipids is relatively common among mycobacterial species, the production of mycolactone as a cell-associated or secreted molecule appears so far to be restricted to
M.
ulcerans
.
Related Results
Therapeutic efficacy of lascufloxacin in patients with
Mycoplasma pneumoniae
pneumonia
Therapeutic efficacy of lascufloxacin in patients with
Mycoplasma pneumoniae
pneumonia
ABSTRACT
The prevalence of macrolide-resistant
Mycoplasma pneumoniae
in Japan is increasing once agai...
Inhibition du translocon Sec61 dans le traitement du myélome multiple
Inhibition du translocon Sec61 dans le traitement du myélome multiple
Le myélome multiple (MM) est un cancer hématopoïétique caractérisé par la prolifération incontrôlée de plasmocytes tumoraux dans la moelle osseuse des patients. La sécrétion de gra...
The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement.
The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement.
Lysosomotropic amines, such as ammonium chloride, are known to protect cells from the cytotoxic effects of diphtheria toxin. These drugs are believed to inhibit the transport of th...
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like ...
Cell death analysis of recombinant mature epsilon toxin on the kidney cell line
Cell death analysis of recombinant mature epsilon toxin on the kidney cell line
Background and Objectives: Epsilon toxin is the third hazardous bacterial toxin causing ABS enterotoxaemia in domestic animal. In addition, epsilon toxin is known as a biological w...
Clinical efficacy of macrolide antibiotics in mycoplasma pneumoniae pneumonia carrying a macrolide-resistant mutation in the 23 S rRNA gene in pediatric patients
Clinical efficacy of macrolide antibiotics in mycoplasma pneumoniae pneumonia carrying a macrolide-resistant mutation in the 23 S rRNA gene in pediatric patients
Abstract
Background
The global prospective surveillance data showed the re-emergence of mycoplasma pneumoniae pneumonia (...
Clinical Efficacy of Macrolide Antibiotics in Mycoplasma Pneumoniae Pneumonia Carrying a Macrolide-resistant Mutation in the 23S rRNA Gene in Pediatric Patients
Clinical Efficacy of Macrolide Antibiotics in Mycoplasma Pneumoniae Pneumonia Carrying a Macrolide-resistant Mutation in the 23S rRNA Gene in Pediatric Patients
AbstractBackground. These global prospective surveillance data showed the re-emergence of mycoplasma pneumoniae pneumonia (MPP) in Europe and Asia after the coronavirus disease 201...
Antibiotic Potentiation as a Promising Strategy to Combat Macrolide Resistance in Bacterial Pathogens
Antibiotic Potentiation as a Promising Strategy to Combat Macrolide Resistance in Bacterial Pathogens
Antibiotics were once called miracle drugs which hit the market with astounding impact as it was considered the ultimate cure for infectious diseases in the mid-20th century. Howev...

